CAVA is 'not a cheap stock.' Investors should buy it anyway, Morgan Stanley says

Morgan Stanley upgraded CAVA Group to overweight from equal-weight and raised its 12-month price target to $90 from $86, implying 29% upside from Tuesday’s close. The note argues valuation is defensible despite the stock’s ~21% pullback over three months, citing strong fundamentals such as traffic/unit growth and margin visibility, with 2Q and FY guidance expected to stay on track. Street views are broadly aligned (17 of 29 analysts rate it buy/strong buy), limiting the chance of an immediate market-wide move but likely supporting the stock.

Analysis

The market is treating CAVA as a scarce-growth asset, which is why the right lens is not near-term earnings power but the durability of unit economics. At a mid-40s EV/EBITDA multiple, the stock behaves like a long-duration compounder: if traffic and new-store productivity stay intact, the multiple can stay elevated even without explosive same-store sales. But that also means the equity is highly sensitive to any evidence that growth is becoming more capital-intensive or more promotional than the model assumes.

Second-order, the real competitive pressure is on other premium fast-casual concepts and on any operator chasing the same health-forward lunch/dinner occasion. If CAVA’s brand remains resilient, it can force peers to spend more on marketing and menu innovation just to defend traffic, which is a margin headwind for lower-quality growth names. Conversely, if the consumer trade-down weakens, CAVA is not immune: premium tickets can be deferred quickly, and the valuation leaves little room for a quarter or two of merely okay comps.

The catalyst path is mostly 1-3 months into the next print, not today. The buy case is that management keeps FY guidance intact and unit openings continue to show strong early productivity; the bear case is that the recent stall in comp momentum proves this is a one-factor story dependent on new-store cadence rather than broadening demand. The consensus is already constructive, so this upgrade is less a fresh fundamental discovery than a signal that bearish positioning may be crowded out only if the next data points show re-acceleration.

Key Decisions for Investors

• Tactically buy CAVA only on post-upgrade weakness, targeting the next 1-3 month earnings window; use a 15-20% downside stop if same-store sales do not reaccelerate.
• Pair trade: long CAVA / short SG over 1-3 months to express quality growth versus higher execution risk in premium fast-casual; thesis fails if SG shows faster traffic inflection or CAVA comps stay flat.
• For existing CAVA longs, consider call spreads rather than outright stock into the next print to capture a re-rating without paying full valuation for unlimited upside.
• Set an alert on the next quarterly comp and FY guidance: if guidance is not reaffirmed or unit productivity slips, expect a fast multiple reset rather than a slow grind lower.